DataM Intelligence | competitive Intelligence Spinal Muscular Atrophy treatment is evolving fast, with gene therapy, oral drugs, and next-g ...

Despite a robust cash position, Revolution Medicines' high burn rate and lofty valuation increase risk and sensitivity to ...

Novartis’ Zolgensma gene therapy for spinal muscular atrophy is the most expensive drug in the world, but that hasn’t stopped it making a strong start in the US market. Zolgensma (onasemnogene ...

The FDA revealed earlier this month that it may take action against Novartis after discovering that data filed to support approval of Zolgensma (onasemnogene abeparvovec) – a spinal muscular ...

A new method developed by researchers at KAIST and Chungnam National University could drastically streamline drug interaction ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...